Abstract
While only used initially in cases with resistance to subcutaneous insulin therapy, intraperitoneal insulin therapy provides an overall more stable glucose control than subcutaneous insulin therapy thanks to its pharmacokinetics as pointed by Garcia-Verdugo et al from the experience of implantable insulin pumps. The expansion of these devices has been limited by underdelivery issues and high cost. The availability of a new percutaneous access to intraperitoneal route could allow a similar glucose control with less constraints of follow-up and expected lower cost. Currently reported clinical experience does not allow a reliable assessment of its main risk of infection which could impair its sustained usability. Because intraperitoneal insulin could allow a fully automated closed-loop insulin delivery, a specific interest for its means of performance is relevant.